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Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) have been proposed for prevention and treatment
of a variety of human cancers. Piroxicam, in particular, has been recently shown to exert significant
anti-tumoral activity in combination with cisplatin (CDDP) on mesothelioma cells. However, the
mechanisms through which NSAIDs regulate the cell cycle as well as the signal pathways involved
in the growth inhibition, remain unclear. In the present study, using two mesothelioma cell lines,
MSTO-211H and NCI-H2452, we have investigated the influence of piroxicam alone and in
association with CDDP on proliferation, cell cycle regulation and apoptosis. In both cell lines a
significant effect on cell growth inhibition, respect to the control, was observed with all the drugs
tested. Moreover, treatment with piroxicam or CDDP alone altered the cell cycle phase
distribution as well as the expression of some cell cycle regulatory proteins in both cell lines. These
effects were increased, even if in a not completely overlapping manner, after treatment with the
association of piroxicam and CDDP. In particular, the two drugs in NCI cell line had a synergistic
effect on apoptosis, probably through activation of caspase 8 and caspase 9, while the most evident
targets among the cell cycle regulators were cyclin D1 and p21waf1. These results suggest that the
association of piroxicam and CDDP specifically triggers cell cycle regulation and apoptosis in
different mesothelioma cell lines and may hold promise in the treatment of mesothelioma.
Background
Nonsteroideal anti-inflammatory drugs (NSAIDs) are
commonly used as anti-inflammatory and analgesic
drugs. However, several epidemiological studies have
found that treatment with NSAIDs is associated with a
reduced risk for cancer [1,2]. Since then, the antineoplas-
tic effects of NSAIDs have been evaluated in many rand-
omized clinical trials [3-8]. NSAIDs inhibit
cyclooxygenases (COX-1 and COX-2), key enzymes in ara-
chidonic acid metabolism, which catalyze an intermedi-
ate step in the production of prostaglandins, prostacyclins
and thromboxanes [9]. Although COX-1 is constitutively
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expressed in many tissues, COX-2 is detected negligibly in
most tissues but can be induced by cytokines and stress in
various cell types. In several cancers COX-2 is over-
expressed and this over-expression appears to be involved
in the development of cancer by promoting cell division
[10,11], inhibiting apoptosis [12,13], altering cell adhe-
sion and enhancing neovascularization [14-16]. The inhi-
bition of COX-2 by NSAIDs blocks these activities and,
thus, may account for the anti-carcinogenic effects of these
drugs. However, NSAIDs can also act through COX-inde-
pendent mechanisms and each NSAID appears to have its
own, more or less specific, COX-independent target
[17,18]. Recently, an overexpression of COX-2 has been
demonstrated in malignant mesothelioma [19-21] and
this has provided the rationale to explore the use of COX
inhibitors for the prevention and/or treatment of this
tumour.
Malignant mesothelioma (MM) is one of the most lethal
human tumours, which incidence is expected to increase
in Europe within the next 20 years [22]. Prognosis is poor
and patients have a median survival of few months in
either treated or untreated cases [23,24]. Mesothelioma
represents a therapeutic problem since it is resistant to
radiation, chemotherapy or surgical resection. Recent ran-
domized studies on treatment of mesothelioma with
combined chemotherapy demonstrate a survival benefit
when a combination of cisplatin and antifolate drugs has
been used [25,26]. Moreover, the combination of chemo-
therapy followed by surgery supplemented by postopera-
tive radiotherapy in cases of incomplete resection, seems
to be a promising treatment [27]. Unfortunately, none of
these forms of treatment has significant impact on the
progression and the outcome of mesothelioma and new
therapeutic approaches must be investigated for a more
successful treatment of this disease. Recently, the anti-
tumour effects of NSAIDs have been studied on in vitro
and  in vivo experimental MM models. In particular,
NS398 has produced a significant reduction of prolifera-
tion level in MM cell lines established and derived from
previously untreated patients [28] and celecoxib has
proved to be efficient in inhibiting mesothelioma cell
growth [29] In a previous work we have demonstrated a
significant anti-proliferative effect of piroxicam in two
mesothelioma cell lines (MSTO-211H and NCI-H2452),
not expressing COX-2, treated with piroxicam alone or in
combination with CDDP [30]. The combination of the
two drugs resulted in a synergistic effect, suggesting that
piroxicam sensitizes mesothelioma cells to CDDP cyto-
toxicity. This result was confirmed also in vivo, by using a
mesothelioma flank tumour model and a mesothelioma
orthotopic tumour model [30].
In this work we have investigated the molecular mecha-
nisms of cell cycle perturbation caused by piroxicam,
CDDP and their association in two mesothelioma cell
lines MSTO-211H and NCI-H2452. The resulting knowl-
edge of the biological events elicited by these drugs in
exerting their anti-tumour effects, could represent the
basis for identifying specific molecular target of mesothe-
lioma cells and for leading to advances in therapy.
Methods
Reagents
Piroxicam (FELDENE; Pfizer, New York, NY) was supplied
as a 60 mmol/L injectable solution and CDDP (Pharma-
cia-Italia, Nerviano, MI, Italy) as a 50 mmol/L injectable
solution. Primary mouse monoclonal antibody against
human p27Kip1 (p27) and primary rabbit polyclonal anti-
body against human p21waf1 (p21) were supplied by S.
Cruz Biotechnology, Inc. Santa Cruz, CA, U.S.A.. Anti cyc-
lin D1 (Cyc D1) monoclonal antibody was supplied by
Cell signalling Technology, Inc. Danvers, MA, U.S.A. and
anti cyclin A (Cyc A) monoclonal antibody by Calbio-
chem, EMD Chemicals, Inc. La Jolla CA, U.S.A. Anti actin
monoclonal antibody was supplied by SIGMA, Saint
Louis, Missouri, U.S.A. and anti COX-2 monoclonal anti-
body by Cayman Chemical, Ann Arbor, MI, U.S.A. Horse-
radish peroxidase-conjugated secondary antibodies were
supplied from Santa Cruz Biotechnology, Inc. Santa Cruz,
CA, U.S.A., and ECL and Super ECL Western blotting
detection reagents from Amersham-Pharmacia, Uppsala,
Sweden.
Cell lines
The human mesothelioma cell lines MSTO-211H (MSTO)
and NCI-H2452 (NCI) were purchased from the Ameri-
can Type Culture Collection (Rockville, MD). Cells were
cultured as monolayers in flasks using American Type
Culture Collection complete growth medium in a humid-
ified atmosphere containing 5% CO2 at 37°C.
Cell treatment with piroxicam and CDDP
Cells were seeded in complete growth medium and 16
hours later were treated with piroxicam and CDDP alone
or in combination (administered at the same time) for 3
h, 6 h, 24 h, 48 h. MSTO were treated with piroxicam 0.76
mM (IP 50 [30]) and CDDP 4.5 µg/ml (IP 50 [30]); NCI
were treated with piroxicam 0.68 mM (IP 50 [30]) and
CDDP 10 µg/ml (IP 50). Controls were untreated.
Cell growth
Cells were treated as mentioned above and were counted
3, 6, 24 and 48 hours after beginning of treatment. Exper-
iments were repeated in triplicate and media values were
calculated. Cell growth was expressed as percent of con-
trol (untreated cells) and was compared between different
treatment groups by Bonferroni test. P values < 0.05 was
regarded as statistically significant. SPSS software (version
14.00, SPSS, Chicago) was used for statistical analysis.Journal of Translational Medicine 2008, 6:27 http://www.translational-medicine.com/content/6/1/27
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Cell cycle analysis on cancer cells
Unsynchronized cells in the mid log phase were seeded at
a density of 106 in T25 flasks. After 16 hours, cells were
treated with piroxicam and/or CDDP, as described in the
previous section. At 24 and 48 hours, adherent and float-
ing cells were harvested, resuspended in staining solution
containing propidium iodide (50 µg/ml), RNAse A,
sodium citrate (0.1%), NP40 (0.1%) in PBS 1×, and incu-
bated for 30 minutes in the dark. Cell cycle distribution of
20.000 cells was analyzed with a FACScalibur flow cytom-
eter (Becton Dickinson, Franklin Lakes, NJ) by ModFit
version 3 Technology (Verity) as previously reported
[31,32]. Pre-G1 picks were analysed as indicative of sub-
G1 apoptotic population. All the experiments were per-
formed at least 3 times and values were expressed in mean
± SD.
Caspase 3, 8 and 9 assays
Caspase activity was detected within whole living cells
using BIOMOL and B-BRIDGE Kits supplied with cell-per-
meable fluorescent substrates. The fluorescent substrates
for caspase 3, 8 and 9 were respectively FAM-DEVD-FMK,
FAM-LETD-FMK, FAM-LEHD-FMK. Cells were washed
twice in cold PBS and incubated for 1 h in ice with the cor-
responding substrates as recommended by suppliers.
Cells were analysed after washing using the CellQuest
software applied to a FACScalibur (BD). Experiments were
performed in triplicate and values were expressed in mean
± SD.
Protein analysis by western blotting
Cell lysates were prepared by treating cells with ice-cold
lysis buffer (Roche Applied Science, Mannheim, Ger-
many) for 20 minutes followed by centrifugation at 4°C
for 15 minutes. 40 µg of proteins were separated on 10%
SDS-PAGE gels and then transferred on polyvinylidene
fluoride (PVDF) membrane. For p21 and Cyc D1 detec-
tion in NCI were used 80 µg of proteins. Membranes were
incubated with specific antibodies diluted 1:250 (p21,
p27 and Cyc A), 1:500 (anti Cyc D1) and 1:1,000 (anti
COX-2). Probing with anti-actin antibody diluted
1:10,000 was used to normalize the sample loading.
Horseradish peroxidase-conjugated secondary antibodies
were used at 1:3,000 dilution. Antibody reaction was vis-
ualized using ECL and Super ECL Western blotting detec-
tion reagents. The experiments were done in triplicate
with comparable results and electrophoretic bands were
analyzed by Scion Image program.
Prostaglandin E2 assay
Prostaglandin E2 levels were detected in medium from
cell culture by using the Correlate-EIA High Sensitivity
Prostaglandin E2 Enzyme Immunoassay kit from Assay
Designs (Ann Arbor, MI).
Results
Effects of piroxicam alone and in combination with CDDP 
on mesothelioma cells growth
To determine the effects of piroxicam alone or in combi-
nation with CDDP on cellular growth, MSTO and NCI
cells were treated with the two drugs (as described in
Methods) for different times. Cell growth was assessed by
cell counts using as control the untreated cells (Fig 1). In
both cell lines a significant effect on cell growth inhibi-
tion, respect to the control, was observed at 24 and 48
hours with all the drugs tested. Interestingly, in MSTO the
combination of piroxicam and CDDP resulted in a
stronger growth inhibition, respect to the other treat-
ments, at 3 and 6 hours.
COX-2 and prostaglandin E2 protein expression levels in 
the MSTO and NCI cell line
In order to determine if some of the anti-proliferative
effects of piroxicam were due to its role as COX inhibitor,
COX-2 protein levels in MSTO and NCI cells were
assessed by western blot. Both mesothelioma cell lines
expressed not detectable level of COX-2 (fig. 2). As posi-
tive controls, a human prostate cancer cell line (PC3)
lysate expressing high levels of COX-2 [30], a human oste-
osarcoma cell line (U-2 OS) lysate expressing low levels
[unpublished results], and ovine COX-2 standard were
used. The not detectable expression of COX-2 was further
confirmed by the lack of detectable levels of prostaglandin
E2 in cell medium analyzed (detection limit for the used
kit was 8 to 10 pg/ml) (data not shown).
Effects of piroxicam alone and in combination of CDDP on 
Cell Cycle Phase Distribution
To dissect the effects on cell cycle distribution of the treat-
ment with piroxicam and/or CDDP, we performed FACS
analysis (fig. 3). Cells were treated with piroxicam and/or
CDDP for 24 and 48 hours. Cell cycle analysis on MSTO
(fig. 3 left panel) showed that piroxicam was able to
induce only a mild alteration, in particular a decrease in
the S and an increase in the G1 phase of the cell cycle. On
the other hand, CDDP treatment induced a significant
block of the cells in S phase at 24 hours that, subse-
quently, evolves in part in apoptosis and in part into G2/
M phase. Cell cycle analysis on NCI (fig. 3 right panel), on
the other hand, showed that piroxicam was not able to
induce a significant modification in the cell cycle distribu-
tion, except for a slight increase in the apoptosis fraction.
CDDP, on the contrary, caused, as in MSTO, an increase
in the S and apoptotic fractions, while it determined a
complete disappearance of cells in G2/M phase.
The results obtained with the combination of the two
drugs showed a stronger and sinergic induction of apop-
tosis respect to single treatment in both cell lines.Journal of Translational Medicine 2008, 6:27 http://www.translational-medicine.com/content/6/1/27
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Piroxicam and CDDP treatment induces caspase 
activation
In order to deeply investigate the apoptotic pathways acti-
vated by the two drugs, we monitored the enzymatic activ-
ity of the initiator caspases 8 and 9 and of the effector
caspase 3 using flow cytometry technology (fig. 4). When
apoptosis was analysed by caspase 9 and 8 activity in
MSTO and NCI, we observed that, in both cell lines, cas-
pase 9 was activated more in presence of the double treat-
ment, which thereby showed at least an additive effect in
induction of cell death. On the other hand, caspase 8 was
significantly activated in MSTO by both the single drugs
and their combination in a similar manner, whereas in
NCI all treatments only produced a slight increase. Aim-
ing to understand the effects of these initiatior caspase
activations, we tested the activity of the effector caspase 3
in these conditions. As shown in fig. 4, we detected in NCI
an increased activation by the combined treatment,
whereas MSTO seems more directly sensitive to the CDDP
treatment alone. The effects of treatments in NCI is in
agreement with the hypothesis that piroxicam and CDDP
cooperates for the induction of apoptosis via caspase 8, 9
and 3.
Effects of piroxicam alone and in combination with CDDP 
on cell cycle regulatory proteins
To identify the molecular pathways targeted by the two
drugs, the expression levels of several cell cycle regulatory
Inhibition of MSTO (left panel) and NCI (right panel) by piroxicam and/or CDDP Figure 1
Inhibition of MSTO (left panel) and NCI (right panel) by piroxicam and/or CDDP. MSTO and NCI were treated for 
the indicated time periods as previously specified. Cell growth was assessed by cell counts and was expressed as percent of 
control (untreated cells). Experiments were repeated in triplicate and media values were calculated and indicated in the upper 
table. P values at the different points of the treatments respect to the control and of the combined treatment (P+C) respect to 
the single drugs treatment were indicated in the lower tables. CTRL = control; P = piroxicam; C = CDDP.
COX-2 expression level in MSTO and NCI cell lines at two  different times Figure 2
COX-2 expression level in MSTO and NCI cell lines 
at two different times. Ovine COX-2 standard, PC-3 
(human prostate cancer cell line) lysate were used as positive 
controls and U-2 OS lysate as negative control. Normaliza-
tion with actin level. The experiments were done in triplicate 
with comparable results.Journal of Translational Medicine 2008, 6:27 http://www.translational-medicine.com/content/6/1/27
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proteins were determined by western blotting in MSTO
and NCI cells treated with piroxicam, CDDP and a combi-
nation of piroxicam and CDDP.
In both cell lines we observed a decrease of Cyc D1 (fig.
5), and in NCI an evident increase of p21 expression (fig.
6), after treatment with piroxicam or CDDP. Interestingly,
in NCI cell line the effect on p21 was more evident when
a combination of CDDP and piroxicam was used.
No appreciable changes were observed in the levels of Cyc
A and p27 in both mesothelioma cell lines with all the dif-
ferent drug treatments (data not shown).
Discussion
MM is an insidious tumor with a dismal prognosis. Due
to the low incidence of the disease, only few randomized
studies have been performed to date. The reported
response rates to the different therapeutic protocols
ranged from 10 to 45% with no clear advantage in terms
of survival that is between 4 and 12 months [25,33]. Var-
ious drugs have been tested in different combinations so
far; among the most commonly employed are doxoru-
bicin, cyclophosphamide, CDDP, carboplatin, gemcitab-
ine, and pemetrexed. Recently, a benefit in response rate
was observed with a combination of premetrexed and cis-
platin and, similarly, by adding raltitrexed to cisplatin
alone [25,26]. However, new and more effective chemo-
therapic drugs are urgently required for a more successful
treatment of this deadly disease.
Cancer, indeed, is viewed now not only as being the con-
sequence of uncontrolled proliferation, but is also consid-
ered to be the result of an altered balance between cell
proliferation and cell apoptosis. Therefore, therapies com-
bining abrogation of cell cycle checkpoints and enhance-
ment of the cell death mechanisms should be investigated
in MM.
Our previous studies demonstrated that piroxicam
induced a significant inhibition of proliferation in two
mesothelioma cell lines (MSTO and NCI). Moreover, we
demonstrated a marked tumour growth inhibition and an
extended survival of mice treated with a combination of
piroxicam and CDDP in peritoneal mesotheliomas
induced by MSTO intra-peritoneal injection [30].
Intrigued by the possible convergent activities exerted by
CDDP and piroxicam, we studied the effects of those treat-
ments in single dosage or in combination on cell growth
in NCI and MSTO cells. Our data suggest that piroxicam
has anti-proliferative effects in both cell lines, a finding
that is consistent with data from the literature showing
that piroxicam may target multiple component of the
molecular machinery regulating cell cycle. Moreover, in
MSTO, piroxicam in association with CDDP caused a
Effects of piroxicam and/or CDDP on cell cycle regulation in MSTO (left panel) and NCI cells (right panel) Figure 3
Effects of piroxicam and/or CDDP on cell cycle regulation in MSTO (left panel) and NCI cells (right panel). 
Cells were treated with piroxicam and/or CDDP for 24 and 48 hours and analyzed to determine cell cycle phase distribution. 
All the experiments were performed at least 3 times. Media ± Standard deviation of experiments is expressed as percentage of 
total cells. CTRL = control; P = piroxicam; C = CDDP.
Determination of enzymatic activity of the caspase (CASP) 3,  8 and 9 Figure 4
Determination of enzymatic activity of the caspase 
(CASP) 3, 8 and 9. Following 16 h treatments with piroxi-
cam and/or CDDP as indicated, the activity of caspase 3, 8 
and 9 was measured and expressed as percentage ± Standard 
deviation of total cells. Experiments were performed in tripli-
cate. CTRL = control; P = piroxicam; C = CDDP.Journal of Translational Medicine 2008, 6:27 http://www.translational-medicine.com/content/6/1/27
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stronger growth inhibition at 3 and 6 hours respect to the
single drug treatments. Based on the fact that in both cell
lines the level of COX-2 is very low and PGE2 is undetec-
table, we assume that piroxicam in these cells exerts its
anti-proliferative activity via COX-2/prostaglandin E2-
independent mechanisms. These data confirm recent
reports that some of the anti-proliferative and anti-neo-
plastic effects of NSAIDs are independent of the inhibi-
tion of COX enzymes [34-36]. For example, in colon
carcinoma the regulation by NSAIDs of the molecular
pathways of cellular proliferation includes modulation of
Ras and MAP Kinase signal transduction pathways,
nuclear factor kB protein activation and cyclin expression
[37-40]. Moreover, the treatment of human colon carci-
noma cells either with indomethacin or aspirin results in
a decrease in β-catenin/TCF transcriptional activity and
cyclin D1 expression [41].
To dissect the effects on cell cycle distribution and apop-
tosis of the treatment with piroxicam and/or CDDP, we
performed FACS analysis. This analysis demonstrated that
the combination of the two drugs is able to perturb the
cell cycle regulation of the mesothelioma cells in a not
completely overlapping manner in the two cell lines. In
particular, in MSTO cells the combination of the two
drugs was very effective in causing an important increase
of apoptotic fraction essentially due to CDDP action.
Probably, the slight increase of apoptotic index between
CDDP alone and the combined treatment is not a conse-
quence of a direct action of piroxicam on cell cycle distri-
Effects of piroxicam alone and in combination with CDDP on cell cycle regulatory proteins Figure 5
Effects of piroxicam alone and in combination with CDDP on cell cycle regulatory proteins. CycD1 was analysed 
by western blotting in MSTO (left side) and NCI (right side) treated with piroxicam and/or CDDP for different times. Electro-
phoretic bands were analyzed using Scion Image program. Experiments were repeated in triplicate and media values and stand-
ard deviations were calculated. CTRL = control; P = piroxicam; C = CDDP.Journal of Translational Medicine 2008, 6:27 http://www.translational-medicine.com/content/6/1/27
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bution but is the result of a sensibilization of cells to
CDDP action, as we previously demonstrated [30]. On the
other hand, in NCI cells there is an important synergic
effect on apoptosis. In this last case the better efficacy of
the combined treatment could be correlated with the
increase of the three analyzed caspases. This is in agree-
ment with the hypothesis that piroxicam and CDDP
cooperate for the induction of apoptosis via caspase 8, 9
and 3 activation in NCI cells. Nevertheless, the greater
sensitivity of the MSTO cell line to apoptosis induced by
the single CDDP is in line with the higher caspase 8 and 9
activation.
Our data support previous observations [30,42,43] of a
synergistic effect of piroxicam, when used in combination
with CDDP on cell cycle regulation and apoptosis. Inter-
estingly, the specific check-points affected by this treat-
ment are not overlapping in different cell lines, this
demonstrating that the effects of piroxicam could be on
multiple targets. In our experimental model, when we
looked at the molecular regulators of cell cycle, we
detected in MSTO and NCI a significant down-regulation
of Cyc D1 and in NCI an up-regulation of p21 expression
level. These effects are consistent with the results of
growth inhibition described above. Interestingly, our
research group has recently demonstrated that p21 expres-
sion is correlated with prognosis in mesothelioma
patients, thus further confirming the key role played by
this molecule in mesothelioma progression [44,46]. Nev-
ertheless, genomic and proteomic technologies should be
used to confirm and better analyze the molecular effects
demonstrated by our biochemical approach.
Effects of piroxicam alone and in combination with CDDP on cell cycle regulatory proteins Figure 6
Effects of piroxicam alone and in combination with CDDP on cell cycle regulatory proteins. p21 was analysed by 
western blotting in MSTO (left side) and NCI (right side) treated with piroxicam and/or CDDP for different times. Electro-
phoretic bands were analyzed using Scion Image program. Experiments were repeated in triplicate and media values and stand-
ard deviations were calculated. CTRL = control; P = piroxicam; C = CDDP.Journal of Translational Medicine 2008, 6:27 http://www.translational-medicine.com/content/6/1/27
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Conclusion
Piroxicam is a widely used, well tolerated, easily adminis-
trable medication that could be readily associated not
only to CDDP but also to a broad spectrum of chemother-
apy and immunotherapy agents to improve efficacy of
therapeutic protocols for mesothelioma. Our data sup-
port the hypothesis that piroxicam could sensitize mes-
othelioma cells to cisplatin treatment by acting on several
molecular pathways. Indeed, careful molecular dissection
of the molecular pathways elicited or turned off by pirox-
icam treatment should be better carried on by genomic
and proteomic experimental approaches in order to more
clearly define the most suitable targets of this drug and,
eventually, propose the use of piroxicam in clinical trial
setting, even if the cardiac risks associated with COX-
inhibitors should be considered.
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